Mylan Floats Biosimilar Of Mega-Blockbuster Herceptin
Mylan NV on Tuesday said it's seeking U.S. Food and Drug Administration approval of the first biosimilar of Genentech Inc.'s cancer drug Herceptin, a mega-blockbuster that ranks among the world's best-selling drugs....To view the full article, register now.
Already a subscriber? Click here to view full article